Tart Cherry and Omega-3's for Aromatase Inhibitor Musculoskeletal Symptoms
An Open Label, Randomized, Waitlist Controlled Trial of Tart Cherry and Omega-3's for Aromatase Inhibitor Musculoskeletal Symptoms
Sponsor: Philip Chang
A EARLY_PHASE1 clinical study on Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) and Breast Cancer, this trial is actively recruiting participants. The trial is conducted by Philip Chang and has accumulated 12 data snapshots since 2025. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
12 versions recorded-
Mar 2026 — Present [monthly]
Recruiting EARLY_PHASE1
-
Oct 2025 — Mar 2026 [monthly]
Recruiting EARLY_PHASE1
-
Aug 2025 — Oct 2025 [monthly]
Recruiting EARLY_PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jul 2025 — Aug 2025 [monthly]
Not Yet Recruiting EARLY_PHASE1
-
Mar 2025 — Jul 2025 [monthly]
Not Yet Recruiting EARLY_PHASE1
▶ Show 7 earlier versions
-
Jan 2025 — Mar 2025 [monthly]
Not Yet Recruiting EARLY_PHASE1
-
Oct 2024 — Jan 2025 [monthly]
Not Yet Recruiting EARLY_PHASE1
-
Sep 2024 — Oct 2024 [monthly]
Not Yet Recruiting EARLY_PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting EARLY_PHASE1
-
Jun 2024 — Jul 2024 [monthly]
Not Yet Recruiting EARLY_PHASE1
-
Mar 2024 — Jun 2024 [monthly]
Not Yet Recruiting EARLY_PHASE1
-
Dec 2023 — Mar 2024 [monthly]
Not Yet Recruiting EARLY_PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Philip Chang
- The Cherry Marketing Institute
For direct contact, visit the study record on ClinicalTrials.gov .